TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

Michele Maio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.